Virax Biolabs Group Ltd - Class A

Research Virax Biolabs Group Ltd - Class A (VRAX) on Bullrun: market cap USD 21.33M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVRAX
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 21.33M
• Financial periodFY2025
• RevenueUSD 6.33K
• Revenue growth-96.0%
• Net income-USD 6.06M
• Free cash flow-USD 5.17M
• Gross margin-838.2%

Valuation Snapshot

latest market cap is USD 21.33M.

About Virax Biolabs Group Ltd - Class A

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands;

Frequently asked questions

What is Virax Biolabs Group Ltd - Class A's market cap?

Virax Biolabs Group Ltd - Class A's market capitalization is USD 21.33M.

What does Virax Biolabs Group Ltd - Class A do?

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics.